Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.03 USD | +0.86% | -7.09% | +72.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+72.57% | 3.92B | D+ | ||
-20.44% | 10.68B | A- | ||
-6.29% | 2.56B | - | B- | |
-35.49% | 2.12B | C | ||
-21.56% | 1.62B | C+ | ||
+21.53% | 1.05B | B- | ||
+5.46% | 840M | C+ | ||
-17.58% | 512M | C- | ||
-35.10% | 461M | C- | ||
+10.80% | 250M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Iovance Biotherapeutics, Inc. - Nasdaq
- Ratings Iovance Biotherapeutics, Inc.